Met Life Investment Management, LLC Ikena Oncology, Inc. Transaction History

Met Life Investment Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Apr 29, 2024	BUY	$3.5 - $7.31 $42,423 - $88,604	12,121 New	12,121 $79,000
Q2 2023 Aug 10, 2023	BUY	$3.5 - $7.31 $42,423 - $88,604	12,121 New	12,121 $79,000
Q1 2022 May 12, 2022	SELL	$5.61 - $13.85 $65,872 - $162,626	-11,742 Closed	0 $0
Q4 2021 May 17, 2024	BUY	$10.52 - $16.96 $123,525 - $199,144	11,742 New	11,742 $147,000
Q4 2021 Jun 21, 2023	BUY	$10.52 - $16.96 $123,525 - $199,144	11,742 New	11,742 $147,000
Q4 2021 Mar 22, 2023	BUY	$10.52 - $16.96 $123,525 - $199,144	11,742 New	11,742 $147,000
Q4 2021 Feb 15, 2022	BUY	$10.52 - $16.96 $123,525 - $199,144	11,742 New	11,742 $147,000

33.2M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $52.2M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.